

13.47

59%



Fwd: Fw: Submission to International Immunopharmacology – manuscript number

22 Februari 2022 16.53

Dari: **Shabnam Ebrahimi**

DETAIL

— Forwarded Message —

From: huldani huldani <huldanihuldani@gmail.com>
To: "h.abbaszadeh73@yahoo.com" <h.abbaszadeh73@yahoo.com>
Sent: Monday, February 21, 2022, 11:09:25 AM GMT+3:30
Subject: Fwd: Submission to International Immunopharmacology - manuscript number

—— Forwarded message ——

From: International Immunopharmacology <em@editorialmanager.com>
Date: Sat, Jan 8, 2022, 11:25
Subject: Submission to International Immunopharmacology - manuscript number
To: Huldani Huldani <huldanihuldani@gmail.com>

This is an automated message.

Manuscript Number: INTIMP-D-22-00084
Application of extracellular vesicles derived from mesenchymal stem cells as potential therapeutic tool in autoimmune and rheumatic diseases

Dear Dr Huldani,

Your above referenced submission has been assigned a manuscript number: INTIMP-D-22-00084.

To track the status of your manuscript, please log in as an author at <https://www.editorialmanager.com/intimp/>, and navigate to the "Submissions Being Processed" folder.

Thank you for submitting your work to this journal.

Kind regards,
International Immunopharmacology

More information and support

You will find information relevant for you as an author on Elsevier's Author Hub: <https://www.elsevier.com/authors>

FAQ: How can I reset a forgotten password?
https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/kw/editorial+manager/

For further assistance, please visit our customer service site: <https://service.elsevier.com/app/home/supporthub/publishing/>. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email.

#AU_INTIMP#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/intimp/login.asp?a=r>). Please contact the publication office if you have any questions.





Fwd: Fw: PDF for submission to International Immunopharmacology requires approval

22 Februari 2022 16.56

Dari: **Shabnam Ebrahimi**

DETAIL

----- Forwarded message -----

From: **International Immunopharmacology**

<em@editorialmanager.com>

Date: Wed, Feb 2, 2022, 17:50

Subject: PDF for submission to International Immunopharmacology requires approval

To: Huldani Huldani <huldanihuldani@gmail.com>

This is an automated message.

Application of extracellular vesicles derived from mesenchymal stem cells as potential therapeutic tools in autoimmune and rheumatic diseases

Dear Dr Huldani,

The PDF for your above referenced manuscript has been built and requires your approval. If you have already approved the PDF of your submission, this e-mail can be ignored.

Please review the PDF carefully, before approving it, to confirm it appears as you expect and is free of any errors. Once approved, no further changes can be made.

To approve the PDF, please:

* Log into Editorial Manager as an author at:

<https://www.editorialmanager.com/intimp/>.

* Click on the folder 'Submissions Waiting for Author's Approval' to view and approve your submission PDF. You may need to click on 'Action Links' to expand your Action Links menu.

* Confirm you have read and agree with Elsevier's Ethics in Publishing statement by ticking the relevant box.

Once the above steps are complete, you will receive an e-mail confirming receipt of your submission.

We look forward to receiving your approval.

Kind regards,
International Immunopharmacology

More information and support

FAQ: How can I approve my submission?

https://service.elsevier.com/app/answers/detail/a_id/5959/p/-10523/supporthub/publishing/

You will find information relevant for you as an author on Elsevier's Author Hub: <https://www.elsevier.com/authors>

FAQ: How can I reset a forgotten password?

https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/kw/editorial+manager/

For further assistance, please visit our customer service site:

<https://service.elsevier.com/app/home/supporthub/publishing/>.

Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email.

#AU_INTIMP#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at any time.

(Use the following URL: <https://www.editorialmanager.com/intimp/login.asp?a=r>). Please contact the publication office if you have any questions.



Fwd: Fw: PLEASE TAKE ACTION – Share your article [INTIMP_108634]

22 Februari 2022 16:57

Dari:  Shabnam Ebrahimi

Forwarded message

From: Elsevier - Article Status <Article_Status@elsevier.com>

Date: Sat, Feb 19, 2022, 19:20

Subject: PLEASE TAKE ACTION - Share your article [INTIMP_108634]

To: <huldanihuldani@gmail.com>

ELSEVIER

Share your article!

Dear Dr. Huldani,

We are pleased to let you know that the final version of your article *Application of extracellular vesicles derived from mesenchymal stem cells as potential therapeutic tools in autoimmune and rheumatic diseases* is now available online, containing full bibliographic details.



To help you access and share this work, we have created a Share Link – a personalized URL providing **50 days' free access** to your article. Anyone clicking on this link before April 10, 2022 will be taken directly to the final version of your article on ScienceDirect, which they are welcome to read or download. No sign up, registration or fees are required.

Your personalized Share Link:
<https://authors.elsevier.com/a/1echq5aRFnc0yZ>

Click on the icons below to share with your network:



We encourage you to use this Share Link to download a copy of the article for your own archive. The URL is also a quick and easy way to share your work with colleagues, co-authors and friends. And you are welcome to add the Share Link to your homepage or social media profiles, such as Facebook and Twitter.

You can find out more about Share Links on Elsevier.com.

Did you know, as an author, you can use your article for a wide range of scholarly, non-commercial purposes, and share and post your article online in a variety of ways? For more information visit www.elsevier.com/sharing-articles.

Kind regards,
 Elsevier Researcher Support

Increase your article's impact

Our [Get Noticed](#) guide contains a range of practical tips and advice to help you maximize visibility of your article.

Publishing Lab

Do you have ideas on how we can improve the author experience? Sign up for the [Elsevier Publishing Lab](#) and help us develop our publishing innovations!

Have questions or need assistance?

Please do not reply to this automated message. For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions. You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | [Privacy Policy](#) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084
 This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.